ProteoNic Biosciences, a provider of vector technology and services for the production of biologics, today announced a partnership with Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity.
This strategic alliance will grant Ginkgo Bioworks’ customers access to ProteoNic's state of the art vector technology in the field of protein production as well as to novel viral vector technology for cell and gene therapy applications.
This also marks ProteoNic’s joining the Ginkgo Technology Network, an ecosystem of technology partners dedicated to driving innovation in customer R&D programs.
"This collaboration opens a significant opportunity for ProteoNic and its customers,” says Frank Pieper, CEO of ProteoNic. "This partnership aligns with our mission of supporting in producing complex biologics, driving capacity enhancements and achieving cost-of-goods savings in biologics manufacturing, while also tackling critical hurdles in viral vector manufacturing for cell and gene therapies.”
ProteoNic's premium vector technology is broadly applicable across cell lines and product classes, including complex molecules which are difficult to express by conventional technology.
Application of this novel technology enables production of complex molecules at economically viable levels, resolves capacity constraints and reduces manufacturing costs.
Applied to viral vectors, it has the capacity to resolve bottlenecks currently associated with LV and AAV production.
The Ginkgo Technology Network brings together a diverse array of partners, spanning AI, genetic medicines, biologics, and manufacturing, with the aim of integrating their capabilities to provide customers with robust end-to-end solutions for successful R&D outcomes.
